lymphotoxin β receptor | Tumour necrosis factor (TNF) receptor family | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

lymphotoxin β receptor

  Target has curated data in GtoImmuPdb

Target id: 1872

Nomenclature: lymphotoxin β receptor

Systematic Nomenclature: TNFRSF3

Family: Tumour necrosis factor (TNF) receptor family

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 435 12p13 LTBR lymphotoxin beta receptor
Mouse 1 415 Ltbr lymphotoxin B receptor
Rat - - Ltbr lymphotoxin beta receptor
Previous and Unofficial Names
CD18 | LTbetaR | LT-beta receptor | LTBR | lymphotoxin beta receptor (TNFR superfamily, member 3) | TNFCR | TNFR2-RP | TNF receptor-related protein | TNFR III
Database Links
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
UniProtKB
Wikipedia
Natural/Endogenous Ligands
LIGHT {Sp: Human}
lymphotoxin β2α1 heterotrimer {Sp: Human}
Adaptor proteins (Human)
TRAF3, TRAF4, TRAF5
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
LIGHT {Sp: Human} Hs - - -
lymphotoxin β2α1 heterotrimer {Sp: Human} N/A - - -
Immunopharmacology Comments
Interaction of the lymphotoxin β receptor (LTBR) with its ligand is required for the development and organization of the secondary lymphoid organs and is involved in chemokine release (reported to induce interleukin 8 gene expression [2]). The LTBR pathway also drives expression of homeostatic chemokines (CCL19, CCL21, CXCL13) that are associated with the pathological development of ectopic lymphoid-like follicles in the exocrine glands of patients with Sjögren's syndrome. Consequently the CXCL13/LTBR axis is considered as a potential therapeutic target in conditions like Sjögren's syndrome. This is evidenced by the development of pharmaceutical agents that block LTBR activity being advanced to clinical trials (e.g. baminercept (BG9924; Biogen) which is a soluble LTBR-IgG Fc fusion protein [1]). BG9924, was primarily evaluated in clinical trials for active rheumatoid arthritis (RA; NCT00458861). However development in RA was terminated because interim analysis of trial data indicated that BG9924 therapy failed to meet the primary endpoint.
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 1 GO processes
GO:0043011 myeloid dendritic cell differentiation IBA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 1 GO processes
GO:0033209 tumor necrosis factor-mediated signaling pathway TAS
Immuno Process:  Immune system development
GO Annotations:  Associated to 1 GO processes, IEA only
GO:0043011 myeloid dendritic cell differentiation IBA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 1 GO processes, IEA only
GO:0043011 myeloid dendritic cell differentiation IBA

References

Show »

1. Bienkowska J, Allaire N, Thai A, Goyal J, Plavina T, Nirula A, Weaver M, Newman C, Petri M, Beckman E et al.. (2014) Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS ONE, 9 (11): e112545. [PMID:25405351]

2. Chang YH, Hsieh SL, Chen MC, Lin WW. (2002) Lymphotoxin beta receptor induces interleukin 8 gene expression via NF-kappaB and AP-1 activation. Exp. Cell Res., 278 (2): 166-74. [PMID:12169272]

Contributors

Show »

How to cite this page

David MacEwan.
Tumour necrosis factor (TNF) receptor family: lymphotoxin β receptor. Last modified on 26/03/2018. Accessed on 23/08/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1872.